Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
- 2 January 2024
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 38 (2) , 441-459
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patientsHaematologica, 2017
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialThe Lancet, 2017
- Multiple myeloma: patient outcomes in real‐world practiceBritish Journal of Haematology, 2016
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialBlood, 2016
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaNew England Journal of Medicine, 2014
- Improved long-term survival in multiple myeloma up to the age of 80 yearsLeukemia, 2014
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaBlood, 2012
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011